Galera Therapeutics, Inc.
US ˙ OTCPK ˙ US36338D1081

Introduction

This page provides a comprehensive analysis of the known insider trading history of Blackstone Clarus GP L.L.C.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Blackstone Clarus GP L.L.C. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TALS / Talaris Therapeutics Inc 10% Owner 0
US:GRTX / Galera Therapeutics, Inc. 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Blackstone Clarus GP L.L.C.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases GRTX / Galera Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GRTX / Galera Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-11-12 GRTX Blackstone Clarus GP L.P. 80,786 12.0000 80,786 12.0000 969,432 111 17.67 458,057 47.25
2019-11-12 GRTX Blackstone Clarus GP L.P. 52,660 12.0000 52,660 12.0000 631,920
2019-11-12 GRTX Blackstone Clarus GP L.P. 97,131 12.0000 97,131 12.0000 1,165,572
2019-11-12 GRTX Blackstone Clarus GP L.P. 19,423 12.0000 19,423 12.0000 233,076

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GRTX / Galera Therapeutics, Inc. Insider Trades
Insider Sales GRTX / Galera Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GRTX / Galera Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GRTX / Galera Therapeutics, Inc. Insider Trades
Insider Purchases TRML / Tourmaline Bio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GRTX / Galera Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRML / Tourmaline Bio, Inc. Insider Trades
Insider Sales TRML / Tourmaline Bio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GRTX / Galera Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRML / Tourmaline Bio, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Blackstone Clarus GP L.L.C. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -135,334 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -676,774 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -366,918 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -562,891 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -278,707 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -696,767 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -717,160 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -3,586,364 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -1,944,371 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -2,982,874 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -1,476,924 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -3,692,307 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -26,000,000 0 -100.00
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 701 160,044 0.44 17.00 11,917 2,720,748
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 3,507 800,353 0.44 17.00 59,619 13,606,001
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 1,902 433,917 0.44 17.00 32,334 7,376,589
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 2,917 665,676 0.44 17.00 49,589 11,316,492
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 1,444 329,598 0.44 17.00 24,548 5,603,166
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 3,611 823,997 0.44 17.00 61,387 14,007,949
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
P - Purchase 15,918 4,875,730 0.33 17.00 270,606 82,887,410
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 25,296 159,343 18.87
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 126,499 796,846 18.87
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 68,582 432,015 18.87
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 105,213 662,759 18.87
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 52,094 328,154 18.87
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 130,236 820,386 18.87
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 134,047 134,047
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 670,347 670,347
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 363,433 363,433
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 557,546 557,546
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 276,060 276,060
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 690,150 690,150
2021-05-13 2021-05-11 4 TALS Talaris Therapeutics, Inc.
Common Stock
C - Conversion 4,859,812 4,859,812
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series C Redeemable Convertible Preferred Stock
C - Conversion -561,385 0 -100.00
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series C Redeemable Convertible Preferred Stock
C - Conversion -2,807,372 0 -100.00
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series C Redeemable Convertible Preferred Stock
C - Conversion -1,552,035 0 -100.00
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series C Redeemable Convertible Preferred Stock
C - Conversion -2,334,966 0 -100.00
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
P - Purchase 19,423 130,444 17.49 12.00 233,076 1,565,328
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
P - Purchase 97,131 652,324 17.49 12.00 1,165,572 7,827,888
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
P - Purchase 52,660 353,661 17.49 12.00 631,920 4,243,932
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
P - Purchase 80,786 542,555 17.49 12.00 969,432 6,510,660
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 111,021 111,021
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 555,193 555,193
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 301,001 301,001
2019-11-14 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock
C - Conversion 461,769 461,769
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)